Rare Daily Staff
Naia Rare Diseases, a biopharmaceutical company developing drugs for rare gastrointestinal diseases, said it has received authorization from the Medicine and Healthcare Products Regulatory Agency in the United Kingdom to initiate a clinical trial of NB 1001, its experimental therapeutic for adults with short bowel syndrome.
Short bowel syndrome is caused by a lack of functional small intestine and causes diarrhea, malnutrition, dehydration, and weight loss.
NB 1001 is a long-acting glucagon-like peptide-1 and allows for up to once-per-month dosing. The company said it is the only drug in development that directly addresses increased bowel motility in SBS. By slowing gut transit, NB 1001 will allow for better absorption of fluids and nutrients. As a result, it is expected to allow patients to eliminate the need for parenteral nutrition and improve their quality of life. It is also expected to have a better safety profile than other GLP-1 agonists because of its lower overall dose. NB1001 will be administered as a replacement therapy (replacing endogenous GLP-1 lost by bowel resection).
In addition to NB 1001, the company is developing the therapy for pediatric patients and a GLP-2 agonist for an undisclosed rare gastrointestinal disorder.